Welcome to our dedicated page for Annovis Bio SEC filings (Ticker: ANVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Annovis Bio, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing buntanetap for Alzheimer’s disease, Parkinson’s disease, and related neurodegenerative conditions. Recent Form 8-K reports cover operating results, Regulation FD materials, clinical and regulatory updates, material-event disclosure, exhibits, and changes in executive finance leadership.
Proxy materials describe annual-meeting proposals, director elections, stockholder voting procedures, board governance, and the company’s common stock structure. The filings also identify ANVS common stock as a New York Stock Exchange-listed security and provide capital-structure and governance disclosures relevant to the company’s development-stage business.
Annovis Bio director Michael B. Hoffman made a large open-market purchase of the company’s common stock. On April 2, 2026, he bought 713,800 shares at $2.10 per share, increasing his direct holdings to 3,288,539 shares.
He also has indirect ownership of 223,357 shares held by The 2024 Hoffman Family Trust, over which he has both voting and investment power. The filing shows no derivative securities remaining, so this activity reflects a direct cash investment rather than an options exercise.
Annovis Bio, Inc. reported that effective March 23, 2026, Chief Financial Officer Mark Guerin is no longer employed by the company. The company stated that his departure did not arise from any disagreement regarding operations, policies, or practices.
The board of directors is expected to appoint Chief Executive Officer Maria Maccecchini to serve as Acting Chief Financial Officer until a permanent replacement is identified, temporarily combining the CEO and CFO responsibilities.
Annovis Bio, Inc. reported full-year 2025 results while advancing its lead drug buntanetap into later-stage trials. The company initiated a pivotal Phase 3 study in early Alzheimer’s disease and started an open-label extension study in Parkinson’s disease, highlighting biomarker data that suggest a potential disease-modifying effect.
For the year ended December 31, 2025, research and development expenses were $25.2 million versus $20.0 million in 2024, while general and administrative expenses were $4.5 million versus $6.7 million. Total operating expenses reached $29.7 million, leading to a net loss of $28.9 million compared with $24.6 million a year earlier. Basic net loss per share was $1.40 versus $2.02.
Cash and cash equivalents were $19.5 million as of December 31, 2025, up from $10.6 million at year-end 2024. Total stockholders’ equity increased to $16.9 million from $9.3 million, reflecting capital raised to support the expanded clinical program.
Annovis Bio files its annual report describing major progress in its neurodegeneration pipeline centered on lead drug buntanetap. The company is running a pivotal Phase 3 trial in early Alzheimer’s disease, designed with a 6‑month symptomatic readout and 18‑month disease‑modifying component, and an open‑label extension in Parkinson’s disease.
Prior Phase 2/3 AD and Phase 3 PD trials showed statistically significant cognitive and functional benefits in defined subgroups, and the FDA has aligned on a dual NDA path for short‑ and long‑term efficacy in AD. Annovis also highlights earlier‑stage assets ANVS405 for acute brain injury, ANVS301 for later‑stage dementia, and a broad patent estate expected to run into the 2040s.
Annovis Bio reported that an independent Data and Safety Monitoring Board completed a planned 6‑month safety review of its pivotal Phase 3 Alzheimer’s disease trial of buntanetap and recommended the study continue without changes. The DSMB found no safety concerns, and 6‑month safety data in Alzheimer’s patients were consistent with those previously observed in Parkinson’s patients.
The Phase 3 Alzheimer’s trial is recruiting across the United States and is about 40% complete. The first symptomatic efficacy results are expected in early 2027, followed by a disease‑modifying readout in early 2028. The company also noted that, given the aligned safety outcomes across Alzheimer’s and Parkinson’s studies, the FDA indicated it may consider accepting combined safety data in a future NDA submission.
Annovis Bio, Inc. filed a current report describing a planned investor communication. On January 28, 2026, the company will conduct a webinar to present information about its business or programs. The slide presentation for this webinar is being made available as Exhibit 99 and is incorporated by reference into the report.
The filing does not describe the webinar content in detail but makes clear that interested parties can review the full presentation materials through the attached exhibit.
Annovis Bio, Inc. director reported open-market purchases of the company’s common stock. On 12/08/2025, the reporting person bought 30,000 shares at $4.3398 per share and an additional 15,000 shares at $4.24 per share. After these transactions, the reporting person beneficially owned 2,574,739 shares of Annovis Bio common stock directly. An additional 223,357 shares are held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power.
Annovis Bio, Inc. (ANVS) reported an amended Form 4 for a director showing multiple open-market purchases of common stock on 11/24/2025. The director bought 1,489 shares at $4.13, 9,200 shares at $3.85, 415 shares at $4.14, and 28,096 shares at $4.15. After these transactions, the director beneficially owned 2,529,739 shares directly and 223,357 shares indirectly through The 2018 Jane and Michael Hoffman Descendants Trust. The amendment states it was filed to correct the share totals shown in column 5 after each reported transaction, with no other changes to the previously reported trades.
A director of Annovis Bio, Inc. (ANVS) reported several open-market purchases of the company’s common stock. On 11/24/2025, the director bought blocks of Annovis Bio common shares at prices of $4.13, $3.85, $4.14, and $4.15 per share, each coded as a purchase transaction.
Following these transactions, the director beneficially owns 2,519,739 shares of Annovis Bio common stock directly. In addition, 223,357 shares are held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power. The filing confirms the director’s status and that the report is filed for a single reporting person.